Search

Your search keyword '"Ensell, Leah"' showing total 37 results

Search Constraints

Start Over You searched for: Author "Ensell, Leah" Remove constraint Author: "Ensell, Leah"
37 results on '"Ensell, Leah"'

Search Results

1. Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes

2. Nivolumab and ipilimumab for metastatic prostate cancer with an immunogenic signature: The NEPTUNES multi-centre two-cohort, biomarker-selected phase 2 trial.

3. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

4. The impact of viral mutations on recognition by SARS-CoV-2 specific T cells

5. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

6. Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK

8. Investigation of hospital discharge cases and SARS-CoV-2 introduction into Lothian care homes

9. Body composition and lung cancer-associated cachexia in TRACERx

10. The evolution of non-small cell lung cancer metastases in TRACERx

11. The evolution of lung cancer and impact of subclonal selection in TRACERx

12. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

13. Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Factors Associated with Durable Response

14. Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies

15. Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission

16. Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning

17. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study

18. Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission

19. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

20. Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

21. Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasms

22. Abstract LB004: Nivolumab (NIVO) and ipilimumab (IPI) treatment in prostate cancer with an immunogenic signature: cohort 1 of the NEPTUNES multi-centre, two-stage biomarker-selected Phase II trial

23. Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7

24. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study

26. 277 - Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR, in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia and Factors Associated with Durable Response

27. Fc effector function contributes to the activity of human anti-CTLA-4 antibodies

28. Nivolumab and ipilimumab treatment in prostate cancer with an immunogenic signature (NEPTUNES).

29. EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.

30. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.

34. ORCA-2: A phase I study of olaparib in addition to cisplatin-based concurrent chemoradiotherapy for patients with high risk locally advanced squamous cell carcinoma of the head and neck.

35. Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer

37. Feasibility of circulating tumour cell (CTC) enumeration and molecular profiling (MP) as a biomarker in advanced endometrial cancer (aEC).

Catalog

Books, media, physical & digital resources